An Infectious Disease Specialist Named The Main Disadvantage Of Antibodies For COVID-19

An Infectious Disease Specialist Named The Main Disadvantage Of Antibodies For COVID-19
An Infectious Disease Specialist Named The Main Disadvantage Of Antibodies For COVID-19

Video: An Infectious Disease Specialist Named The Main Disadvantage Of Antibodies For COVID-19

Video: Monoclonal Antibodies for COVID-19 Illness and Prophylaxis: Update for Primary Care 2022, November
Anonim

The head of the Gamaleya Research Center for Epidemiology and Microbilology, Alexander Gintsburg, said that a therapeutic drug based on antibodies for the treatment of COVID-19 is being developed in Russia.

The medicine will be administered through a drip. The effect of the treatment should appear in 7-10 days. At the same time, it is possible to create several more similar drugs, the scientist noted. In order to understand which remedy will be more effective, clinical trials will be carried out, they should begin in the fall of 2021.

Vaccinologist, infectious disease specialist and pediatrician Yevgeny Timakov on the air of Sputnik radio called the main drawback of the new treatment method.

So far, the most proven and effective way [to fight coronavirus] is vaccination. But in the future, the development of drugs based on antibodies: a person will have ready-made immunity, and this immunity is fighting coronavirus infection. Is this method promising? Yes, promising. But the question is different, - said the medic.

According to Timakov, obtaining specific purified antibodies is not a cheap process at all. An alternative would be a plasma transfusion with antibodies, but this method is fraught with the development of serious complications in the patient.

And to make a purified drug from antibodies, it will require large laboratory efforts, large investments. Therefore, not every person will be able to afford this drug, - the specialist concluded.

As NEWS.ru reported, at the end of November, the US Food and Drug Administration (FDA) approved the use of an experimental antibody-based serum, which was used to treat US President Donald Trump, who was sick with coronavirus. At the same time, as noted in the FDA, we are not talking about the widespread use of the drug, but only about emergency cases.

Popular by topic